Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication.
Panelists at the recent J.P. Morgan Healthcare Conference in San Francisco, CA were charged with separating the hype from the reality in the field of diagnostics and offered insight into what products will win in the space.
TAI Diagnostics, Inc., focused on developing innovative diagnostic tests for monitoring the health of transplanted organs, announced the final closing of a $10 million Series A preferred equity financing. The company has now raised over $21 million since its inception. The proceeds of this financing will support on-going research and development of TAI’s innovative cell-free DNA (cfDNA) transplant monitoring technology, clinical studies, and the upcoming commercial launch of its post-transplant monitoring assays performed by its CLIA and CAP accredited reference laboratory.
Pfizer has collaborated with Foundation Medicine for the development of companion diagnostics (CDx) for its oncology portfolio.
Alveo Technologies, Inc., ("Alveo" or "the Company") whose mission it is to create affordable and accessible infectious disease diagnostic devices, announced the closing of a $38 million Series A financing raised by Maxim Merchant Capital, a division of Maxim Group LLC. The round was oversubscribed and included existing and new investors. The offering proceeds will be used to advance the optimization and commercialization of Alveo's rapid diagnostic platform for infectious diseases.
US-based gene sequencing firm Illumina has signed an agreement with Guangzhou KingMed Diagnostics Group to co-develop new oncology and hereditary disease testing applications in China.
The overall market value of in vitro diagnostics (IVD) stands at $52 billion this year, and is projected to grow at a compound annual growth rate (CAGR) of 4.2% to $69 billion in 2024. According to GlobalData, a leading data and analytics company.
Researchers at the University of Illinois at Urbana-Champaign have developed technology that enables a smartphone to perform lab-grade medical diagnostic tests that typically require large, expensive instruments. Costing only $550, the spectral transmission-reflectance-intensity (TRI)-Analyzer from Bioengineering and Electrical & Computer Engineering Professor Brian Cunningham’s lab attaches to a smartphone and analyzes patient blood, urine, or saliva samples as reliably as clinic-based instruments that cost thousands of dollars.
Siemens Healthineers has received CE-Mark for its new Atellica Solution with immunoassay and chemistry analysers, which will allow commercial launch in Europe.
UK-based firm Remote Diagnostic Technologies (RDT) has introduced a new system, Tempus ALS, to enable monitoring and defibrillation to improve emergency responses.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.